MedtechWomen Announces Open Registration for Second Annual Conference Designed By and For Women in Medical Technology

MedtechWomen Announces Open Registration for Second Annual Conference Designed By and For Women in Medical Technology

for MedtechWomenNicole Osmer, 650-454-0504

MedtechWomen today announced that registration is now open for MedtechVision 2012: The Empowered Patient, the second annual conference designed by and for women on the forefront of medical innovation. The conference will be held September 11 at the Rosewood Sand Hill in Menlo Park, Calif. A discount of $200 is available for conference attendees who register on or before August 7.

The conference will host more than 20 distinguished panelists and speakers. Victoria Nahum, the founder of the Safe Care Campaign, will deliver the opening keynote, which will focus on the power patients possess to bring change to the medtech industry. Molly J. Coye, M.D., M.P.H., chief innovation officer of the UCLA Health System, will deliver the event’s closing keynote, which will provide insight into how providers are adapting their care delivery models and leveraging innovation to create more patient-centered care.

“We were thrilled with the overwhelmingly positive response to the inaugural MedtechVision conference last year,” said Amy Belt, director of Covidien Ventures and co-founder of MedtechWomen. “We are excited to once again bring together women leaders in medical devices and diagnostics for a content-driven discussion of key opportunities and challenges facing the medtech industry today. The goal of the conference is to understand and appreciate the significant changes affecting the healthcare industry in order to guide medtech innovation and investments towards solutions.”

“The theme of the conference this year – the empowered patient – reflects the increasingly important concept of patients being active drivers of innovation and change in healthcare,” said Deborah Kilpatrick, Ph.D., MedtechWomen co-founder. “More than ever before, the ability of business leaders, physicians, policymakers, and investors to meet patient needs and expectations will greatly impact the future effectiveness of the medtech industry."

Panel topics include:

Conference panelists include executives from the American Liver Foundation, Asthmatx, Arboretum Ventures, Auxogyn, BioCentury, Carolinas HealthCare System, Covidien, CryerHealth, Edwards Lifesciences, Fifer Associates, Genomic Health, ImmuneTech, Joslin Diabetes Center, Marlin & Associates, Medicines360, Mohr Davidow Ventures, Navigenics, Neocure Group, Rock Health, Singularity University, Sonitus Medical, Veracyte, and Viveve.

The conference is supported by lead sponsor Covidien. Additional sponsors include Abbott, Edwards Lifesciences, Fish & Richardson, Essex Woodlands, Mohr Davidow Ventures, K. Fehling & Associates, Venable, Society of Kauffman Fellows, Silicon Valley Bank, and LehmanMillet.

For more information and to register for the conference please visit .

MedtechWomen is a group of women who came together with a vision to highlight and connect women leaders in medical devices and diagnostics. In 2010, they decided to act on their vision of bringing together sector leaders and policymakers to discuss real-world solutions to the most challenging issues facing our industry today. They enlisted the support of their mentors and a broadening circle of colleagues to bring this vision to reality, resulting in the inaugural MedtechVision conference which was held September 15 and 16, 2011, in Menlo Park, Calif.

Founders and organizing members of MedtechWomen are innovators from across the U.S. in varied aspects of the medtech sector, including business leaders, financial investors, researchers, physicians, and experts in new product commercialization.

For more information please visit .

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.